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Abstract 
 
Objective: To investigate the relationship between Major Depressive Disorder (MDD) and 
inflammation assessed using serum C-reactive protein (CRP) in young adults.  CRP has been 
associated with MDD in middle-aged and older adults, but the relationship has yet to be 
established in college-aged adults with MDD. 
 
Methods: This ongoing cross-sectional study included 56 patients with MDD and 106 healthy 
age-matched controls.  Depressed patients were recruited from mental health institutions across 
Connecticut, and were being treated for depression with a Second Generation Antipsychotic 
(SGA).  Questionnaire data, anthropometric measurements and fasting blood draws were 
recorded for all participants.  
 
Results: Young adults with MDD had significantly higher CRP levels than healthy controls 
(p<0.05).   Body Mass Index (BMI) and leptin were positively correlated with CRP (p<0.001) in 
the MDD group, but not in the controls.  Use of Oral Contraception (OC) was positively 
associated with CRP concentrations in both depressed and non-depressed subjects (p<0.010).  
Using, multivariate regression analysis, we were able to account for approximately 42% of the 
variability in CRP in the depressed population.  
 
Conclusions: Our findings indicate that the relationship between CRP and MDD that has been 
established in older adults exists in young adults treated with SGA medication as well.  The 
depressed population had significantly higher CRP and leptin levels, and BMI than controls, 
pointing to a possible role that adiposity and inflammation play in depression. 
 
 
 
 
 
 
 
 
 
 
 
 
C-Reactive Protein (CRP) Levels in a Young Adult Population with  
Major Depressive Disorder (MDD) 
 
Introduction 
  
Major Depressive Disorder (MDD) is a debilitating mental health condition that impacts ones 
quality of life with a force equal to or greater than any other chronic illness (Dowlati et al., 
2010).  The Centers for Disease Control reports that 8% of the total U.S. population over age 12 
currently suffers from MDD, with rates rising higher in specific populations, including young 
adults, and middle aged women (Centers for Disease Control, 2015).  As with many other mental 
health disorders, depression is one of a complex etiology, making treatment a unique challenge 
for each individual.  
 
Over the past decade, increasing evidence has indicated immune system dysregulation in the 
pathogenesis of MDD.  Specifically, an inflammatory component has been highlighted (Raison 
& Miller, 2011).  Several serum proteins, including C-reactive protein (CRP), have been 
implicated in this relationship between inflammation and depression.  CRP, an acute phase 
reactant protein, is of particular importance in the inflammatory response system (IRS).  CRP 
levels above 1 mg/dL can indicate a plethora of deleterious conditions including, cardiovascular 
disease (CVD), metabolic syndrome (MetS), and obesity, and levels above 0.3 mg/dL is 
characterized as low-grade inflammation (LGI) (Sørensen et al. 2014). 
 
Although the association has been made between CRP and increased CVD risk, the link between 
CRP and MDD has remained unclear (Ma et al., 2011).  Nonetheless, both Ma et al. (2013) and 
Cizza et al. (2009) reported elevated CRP in depressed middle-aged women using 
postmenopausal and premenopausal cohorts respectively.  This association has been reported in 
middle-aged men as well (Vetter et al., 2013 & Vogelzangs et al., 2012).  Additionally, 
Vogelzangs et al. (2012) described an association between elevated CRP levels with depressive 
symptoms in a relatively young population (mean age = 41.8), while Song et al. (2015) 
confirmed this in an elderly cohort (mean age = 72.1).  
 
The startling fact that more than one-third of college students found it difficult to function due to 
depression during the past year make them an obvious population for depression research 
(Novotney, 2014).  However, surprisingly few studies have examined the inflammatory link in 
college aged participants with depression, although these CRP studies have been repeated 
numerous times using middle-aged populations.  The negative side effects of depression, while 
serious in all age groups, can manifest themselves in particularly detrimental ways in young 
adults.  This study aimed to investigate whether CRP levels differ between a depressed 18-25 
year old population when compared with a healthy aged match control group, and attempted to 
explain these possible differences.   
Methodology 
 
Participants & Design 
A total of 56 depressed 18-25 year olds and 106 healthy age-matched controls were recruited.  
This depressed cohort was recruited from several mental health institutions in Connecticut.  
Patients were only included in the study if they were being treated with Second Generation 
Antipsychotics (SGAs) for their MDD.  Exclusion criteria were defined as persons who were 
prescribed more than one Second Generation Antipsychotic (SGA) simultaneously, were 
prescribed a dose of SGA below expected doses for patients with MDD, or were prescribed 
medications that would interfere with laboratory tests or physical examination parameters.  A 
control population of 106 healthy 18-25 year old college students was recruited from the 
University of Connecticut – Storrs Campus (UCONN).  Subjects were only enrolled in the 
control group if they had no history of mental illness or treatment for any mental illness.  This 
was ensured by screening each of the 106 control subjects over the phone before offering them 
participation in the study.  In total, all 162 of these young adults underwent the same surveys, 
non-invasive physical examination, and blood work.  The study was conducted jointly between 
the Institute of Living (IOL) in Hartford CT, and at UCONN.  Written informed consent was 
obtained from all subjects prior to beginning the study. IRB approval was obtained separately 
from the IOL and from UCONN prior to beginning the study. 
 
Measurement of Variables 
Sociodemographic questionnaire.  All study participants were administered a questionnaire 
conducted by trained personnel.  The questionnaire relied on self-report data from the 
participants and was designed to account for possible covariates that were adjusted for after data 
collection.  Questions contained content about alcohol consumption (Alcohol Use Disorders 
Identification Test [AUDIT]), sleep quality (Pittsburgh Sleep Quality Index [PSQI]), and 
physical activity.  All subjects were asked to report both their prescription and non-prescription 
medication use over the past three months.  Depression scores were determined using the 
Hamilton Rating Scale for Depression (HAM-D), a validated questionnaire administered by 
trained staff used to diagnose depression (Hamilton, 1960).  
Physical parameters.  Immediately after the survey was completed, a non-invasive physical 
examination was performed on all subjects by trained personnel.  Height (cm) and weight (lbs.) 
were measured using the same calibrated stadiometer and digital scale, and were measured to the 
nearest 0.1 cm and 0.1 lb.  These measurements were used to calculate body mass index (BMI) 
for all participants.  Blood pressure was measured using a OmronTM digital blood pressure 
monitor, HEM-712C.  Bioelectrical Impedance Analysis (BIA) was measured using TanitaTM 
Body Composition Analyzer, TBF-300a.  Waist and hip circumferences (cm) were measured 
using a tape measure and were measured to the nearest 0.1cm. All measurements were done in 
triplicate and averaged.  
Fasting blood measures. Blood samples were collected in the fasting state (≥ 8 hours) in the 
morning by a laboratory professional certified in phlebotomy.  Laboratory tests for CRP and 
leptin were analyzed at clinical laboratories.  CRP levels were measured in a clinical laboratory 
via a particle enhanced immunoturbidimetric assay on the Cobas 6000 /c501 (Roche Diagnostics, 
Indianapolis, IN).  Leptin levels were measured using electrochemiluminescence in a 
commercial laboratory (Quest Diagnostics Nichols Institute, San Juan Capistrano, CA). 
 
Statistical Analyses 
Results are reported as means ± standard deviation (SD).  Descriptive statistics were used to 
characterize continuous and categorical variables collected from interviews, physical exams, and 
fasting blood draws, along with assessing normality of data.  CRP levels were transformed to 
normalize the distribution.  Independent T-tests and ANOVAs were used to compare mean CRP 
levels with other continuous, biological and behavioral variables.  Correlations were run between 
CRP and various biomarkers and anthropometric measurements.  P values <0.05 were considered 
to be significant.  A series of multivariable linear models were run to analyze association of CRP 
with several independent variables.  Included in these models were variables that were found to 
have significant correlations with CRP in simple linear regression models. All analyses were 
conducted using SPSS version 23.0. 
 
Results 
Demographic and descriptive characteristics are presented for all participants (N = 162) in the 
study (Table 1).  This study consisted of 63 men with a mean age of 21.1 ± 1.99 and 99 women 
with a mean age of 20.6 ± 1.80.  Participants were stratified into two groups: patient (those with 
MDD and treated with a SGA) and control (healthy aged matched college students).  Mean CRP 
and leptin levels were significantly higher in the depressed population than in the healthy control 
group (0.44 mg/dl ± .84 vs. 0.16 mg/dl ± .20, p=0.019; 9.41 ng/mL ± 12.05 vs. 5.22 ng/mL ± 
4.91, p=0.015).  Overall, the MDD group were older, had higher serum triglyceride, insulin and 
glucose levels but lower cortisol and HDL levels than the control group.  The MDD group also 
had significantly higher BMIs, waist and hip measurements than the control group (Table 1).  
 
Table 2 and Table 3 stratify CRP data based on gender and oral contraception (OC) use.  There 
was no significant difference in CRP levels between depressed and healthy males (Table 2).  
Significant differences were seen however, when comparing depressed females, and healthy 
females from the control group (.69 mg/dL ± 1.06 vs. .18 mg/dL ± .19 , p=0.012).  Only females 
diagnosed with MDD (N=31) had abnormal CRP levels (>0.50 mg/dL).  Female participants 
were further stratified based on oral contraception (OC) use (Table 3).  No significant 
differences in CRP levels were seen between depressed females who were taking OC and 
depressed females not taking OC, despite higher average CRP levels in the depressed cohort (.98 
mg/dL ± 1.56 vs. .55 mg/dL ± .73, p=0.306). However, in the control group, females taking OC 
had significantly higher CRP levels than females not taking OC (.25 mg/dL ± .18 vs. .11mg/dL ± 
.17, p=0.002). 
 
We have found several correlations between different independent variables and CRP.  In the 
MDD group, CRP was positively correlated with leptin (r=0.585, p=0.000) and BMI (r=0.478, 
p=0.000). When stratifying by gender in the MDD group, leptin was only significantly 
associated with CRP in females (r=.503, p=0.004), however BMI remained significantly 
correlated for males (r=0.412, p<0.05) and females (Figure 1).  No relationship between BMI 
and CRP was seen in healthy males or females (Figure 2).  We also found correlations between 
OC use and CRP.  Leptin (r=0.709, p=0.000) and BMI (r=0.670, p=0.001) were positively 
correlated with CRP in depressed females not using OC.  This relationship was not seen in 
depressed females (r=.309, p=.386; r=.547, p=.102) using OC or in healthy females (NO OC: r=-
.015, p=.930; r=.015, p=.930; YES OC: r=.049, p=.789; r=-.298, p=.098), regardless of OC use.  
 
Multivariate regression analysis determined the variability seen in CRP in the depressed 
population and control group by using significant correlates in the simple linear regression 
models. Our first model included just OC and Leptin and accounted for 38% of the variability in 
CRP values in the depressed population. This model only accounted for 15% of CRP levels in 
the control group. Our best predictive model consisted of OC, leptin, and number of days treated 
with a SGA, and was able to account for 42% of the CRP levels in depressed patients. 
 
Discussion 
CRP has been directly associated with MDD, a relationship that has been shown to be 
bidirectional (Matthews et al., 2010).  To our knowledge, this is the first study to use an 
established MDD population with a healthy age-matched control group to examine the 
relationship between CRP and depression in young adults.  Our findings indicate significantly 
higher CRP levels in a depressed college aged population compared to a healthy control group 
(Table 1).  This confirms the findings of Topíc et al. (2013) who reported that elevated serum 
CRP levels were significantly more common in middle aged MDD patients, than in healthy 
controls 
  
Our results suggest that gender plays a role in CRP differences that we observed between 
depressed and healthy populations.  In males, no significant differences in CRP were noted 
between the experimental and control groups (Table 2).  However, females with MDD had 
significantly higher CRP levels when compared with the controls (Table 2).  These results 
confirm the findings of Cizza et al. (2009) who observed a significant association between 
elevated CRP and MDD in premenopausal women (mean age = 35.5 years).  Identical to our 
results, they also found BMI to be directly correlated with CRP in depressed women, but not in 
controls.  These findings were also reported by Murabito et al. (2013), who observed that 
visceral adipose tissue (VAT) was associated with depressive symptoms in both pre- and post-
menopausal women (mean age = 52.2 years).  No relation between VAT and depression was 
seen in men.  It is well established that VAT is associated with increased serum CRP levels in 
both depressed and non-depressed populations (Murabito et al., 2013; Matthews et al., 2010; 
Sørensen et al. 2014), hinting at the unique synergy between adiposity and inflammation.  
 
Due to its relationship to obesity, numerous studies have implicated leptin in the pathogenesis of 
depression.  Leptin is a hormone synthesized by adipocytes that regulates satiety and energy 
expenditure.  Both increased and decreased levels of the hormone have been linked to obesity 
(Considine et al., 1996).  In addition to associations with BMI, serum leptin concentrations have 
been found to be elevated in both depressed patients and non-depressed patients with metabolic 
syndrome (Jiménez et al., 2009; Chirinos et al., 2013).  Increased adiposity may lead to increased 
inflammation and leptin levels, while it has also been suggested that increased leptin levels can 
cause up-regulation of certain inflammatory cytokines, which may contribute to obesity and 
MDD (Sárvári et al., 2014).  Our results showed that depressed females had significantly higher 
circulating leptin levels than depressed males.  Consistent with previous studies (Morris et al, 
2012), the depressed females in our cohort with high leptin levels also had significantly higher 
BMIs than the healthy controls, hinting at the well-established relationship between the two.  
Conversely, depressed males had similar leptin levels and BMI’s to the healthy male controls.  In 
our multivariate analyses, we found that leptin alone accounted for 31% of the variability in CRP 
levels in depressed patients, adding to the growing body of evidence that leptin may cause 
increased levels of inflammation.  Based on our data, there appears to be gender differences that 
help to explain this relationship.  
 
Second Generation Antipsychotics (SGAs) have been approved by the FDA as appropriate 
adjunct therapy for MDD and have been proven to be effective antidepressants in clinical trials 
(Roberts et al., 2015; Weisler et al., 2012).  However, numerous studies have reported 
antipsychotic induced weight gain (AIWG) and increased levels of inflammation in patients 
treated with SGAs (Dieset et al., 2012; Zhang et al., 2004).  Although AWIG has been well 
documented, the mechanisms involved are not fully understood.  Elevated levels of inflammatory 
cytokines (e.g. CRP) and hormones (e.g. leptin) due to SGAs may be partially responsible, 
however studies are conflicting (Fonseka et al., 2016).  While Dieset et al. (2012) found 
significant inflammatory activation by SGAs in adult psychiatric patients, Kim et al. (2011) 
found no difference in CRP levels among three different SGA treatment groups.  The direction of 
causation between SGAs, inflammation, and hormonal factors is not yet clear, however 
numerous studies have described an association or relationship (Foneska et al., 2016; Sárvári et 
al., 2014; Victoriano et al., 2010).  Although SGAs have been reported to cause increased 
inflammation, these effects were not seen in our study when stratifying for gender.  When 
comparing the CRP levels of healthy males vs. depressed males treated with SGA, no significant 
differences were seen between the groups (.14 mg/dl ± .22 vs .13 mg/dl ± .17 p=0.849).  
However depressed females had significantly higher mean CRP levels when compared with the 
healthy female controls (.69 mg/dl ± 1.06 vs. .18 mg/dl ± .19, p=0.012).  These findings 
highlight the complexity of the relationship between SGAs and inflammation. If SGAs were the 
dominating factor in causing increased CRP in depressed patients, depressed males should have 
also had significantly higher CRP levels than their healthy counterparts.  Instead, we found 
elevated CRP levels only in depressed females vs. healthy females.  This could be because the 
depressed female cohort had significantly higher BMIs than healthy females, which has been 
strongly correlated with increased CRP (Shelton et al., 2015).  It is also well established that 
SGAs alter fat and glucose metabolism due to increased leptin expression (Sárvári et al., 2014).  
No studies however, have examined whether these effects differ based on gender.  Our findings 
indicate that a multifactorial relationship must be considered when attempting to explain CRP 
differences in a depressed vs. healthy population.  
   
Another potential predictor of increased CRP in depressed college-aged adults is the use of OC.  
It is well established that OC use contributes to increased bodily inflammation in both 
adolescents and young adults (Pirkola et al., 2010; Raitakari et al., 2005).  Sørensen et al. (2014), 
found OC use in healthy women (mean age = 38.6) to be a significant predictor of LGI and 
Raitakari et al. (2005) reported OC use to be the single most important determinant of elevated 
CRP levels in healthy women (mean age = 31.7).  The mechanisms by which OC, in particular 
the hormone estrogen, interact with CRP remain unclear, however both biomarkers have been 
linked to increased CVD risk (Van Rooijen et al., 2006).  We found no significant CRP 
differences between females taking OC vs. not taking OC in the depressed group (Table 3).  
However, significant differences in CRP levels were seen in the control group when stratifying 
for OC use, making OC a better predictor of CRP levels in the healthy young females, than in 
depressed young females.  In addition, we found OC alone to account for 28% of the differences 
in CRP in control females.  It is interesting to note that there were no differences in BMI, hip or 
waist circumferences in the female controls when stratifying for OC use, however CRP 
differences were still seen.  According to our results, OC is associated with increased 
inflammation in healthy females, without contributing to any weight gain.  This is not to say that 
OC has no bearing on CRP levels in depressed patients.  We found that OC alone accounted for 
20% of CRP differences in the depressed population.  It is possible however, that the effects of 
OC are somewhat masked in the depressed group due to increased adiposity, diagnosis of MDD, 
and other medication use. 
 
This study has several limitations.  First, since this was a cross-sectional study, all data was 
collected at one time point.  This gave us no access to baseline data on the depressed patients 
before they began treatment with an SGA.  As a result, we were unable to see physical and 
biomarker changes that occurred in patients with MDD treated with SGA. Second, while most 
patients (77.8%) were taking Abilify and Seroquel, others (22.2%) were taking a different SGA 
type.  In addition, the dosing and duration of SGA treatment varied from patient to patient, which 
possibly could have led to variability among biomarkers and anthropometric measurements.  
Third, our current MDD sample size, especially when stratifying by OC, was relatively small 
limiting our generalizability in this group.   
 College students are an important demographic in depression studies for numerous reasons 
including suicide, which is the second leading cause of death among college students (CDC, 
2015).  The negative side effects of depression, while serious in all age groups, can manifest 
themselves in particularly detrimental ways in young adults.  Increased incidence of smoking, 
alcohol consumption, and lack of exercise are all common coping mechanisms, making treating 
and understanding depression in college-aged adults all the more crucial (Beiter et al., 2015).  
While the link between CRP and depression has been well established, we believe our study to 
be the first to examine the relationship between depressive symptoms and inflammation in a 
cohort of young adults (ages 18-25).  To the best of our knowledge, no previous study has used a 
population with a mean age under 30, and most have only shown a relationship between CRP 
and MDD in middle-aged populations.  By using a healthy-aged match control group, we were 
able to observe differences in mean CRP levels between the two groups, and by examining other 
independent variables collected, we have explained some of these differences.  
 
Our findings indicate that the relationship between CRP and MDD that has been established in 
older adults exists in young adults treated with SGA medication as well.   Significant differences 
in CRP, leptin, and BMI were seen when comparing a depressed, 18-25 year old population to a 
healthy age-matched control group, highlighting the important role inflammation plays in both 
adiposity and depression, and how it may connect the two conditions.  In addition, we found that 
OC use and number of days taking a SGA contribute to CRP variability in a depressed 
population.  Future studies are needed to confirm these findings and further understand the 
relationship of elevated CRP in patients with MDD in a larger, more diverse group of college-
aged students.   
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Table 1: Characteristics of Study Participants  
 
 
Total Sample 
(N=162) 
Patient Population 
with MDD (N=56) 
Healthy 
Controls 
(N=106) 
p-value  
Sociodemographics 
    
Age (years) 20.78 21.77 20.25 0.000 
Gender  
    
    Men, N (%) 63 (38.9) 25 (44.6) 38 (35.8) 
 
    Women, N (%) 99 (61.1) 31 (55.4) 68 (64.2) 
 
Physical parameters & 
Biomarkers     
C-reactive protein (mg/dL), 
mean (SD) 
.26 (.53) .44 (.84) .16 (.20) 0.019 
Body mass index (BMI), 
mean (SD) 
24.82 (5.91) 27.92 (8.23) 23.18 (3.21) 0.000 
Insulin (uIU/mL), mean (SD) 11.62 (8.90) 15.37 (13.07) 9.64 (4.78) 0.002 
Leptin (ng/mL), mean (SD) 6.67 (8.33) 9.41 (12.05) 5.22 (4.91) 0.015 
Illiac Crest Average (cm), 
mean (SD) 
82.31 (14.50) 90.80 (18.32) 77.82 (9.37) 0.000 
Mid-illiac Waist (cm), mean 
(SD) 
78.44 (14.17) 87.61 (16.98) 73.59 (9.38) 0.000 
Hip (cm), mean (SD) 96.19 (12.52) 101.26 (17.41) 93.51 (7.77) 0.002 
Triglycerides, mean (SD) 90.17 (45.21) 105.66 (59.05) 81.99 (33.34) 0.007 
Cortisol (ug/dL), mean (SD) 22.96 (10.75) 18.54 (9.34) 25.29 (10.75) 0.000 
High Density Lipoprotein 
(HDL), mean (SD)  
58.69 (14.96) 53.95 (14.30) 61.20 (14.75) 0.003 
Glucose  88.36 (8.43) 90.64 (9.03) 87.15 (7.87) 0.012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: CRP levels By Gender 
 
 MDD (N=56) Controls (N=106) 
 Males 
(N=25) 
Females 
(N=31) 
Males 
(N=38) 
Females 
(N=68) 
CRP (mg/dL), mean 
(SD) 
.13 (.17) .69 (1.06)*# .14 (.22) .18 (.19) 
* p = 0.007 (MDD males vs. MDD females) 
# p = 0.012 (MDD female vs. control females) 
 
 
 
 
Table 3: CRP levels by OC use 
 
 MDD (N=31) Controls (N=68) 
 YES female 
(N=10) 
NO female 
(N=21) 
YES female 
(N=32) 
NO female 
(N=36) 
CRP (mg/dL), mean 
(SD) 
.98 (1.56) .55 (.73) .25 (.18)* .11 (.17) 
* p = 0.002 (Control YES females vs. Control NO females) 
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Figure 1: Body Mass Index (BMI) and                 
C-Reactive Protein (CRP) in Females with 
Major Depressive Disorder (MDD)
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Figure 2: Body Mass Index (BMI) and                 
C-Reactive Protein (CRP) in Females without 
Major Depressive Disorder (MDD)
